Results 1 to 10 of about 51,890 (248)

Multiple myeloma [PDF]

Nature Reviews Disease Primers, 2017
Multiple Myeloma (MM) is a cancer of plasma cells resulting from the abnormal proliferation of malignant plasma cells within the bone marrow (BM) microenvironment. MM accounts for 1.3% of all malignancies and 12% of hematologic cancers, and is the second
Shaji Kumar, S Vincent Rajkumar, Robert A Kyle   +2 more
exaly   +7 more sources

Multiple Myeloma [PDF]

New England Journal of Medicine, 2004
AbstractMultiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present.
Robert A, Kyle, S Vincent, Rajkumar
  +15 more sources

Multiple Myeloma [PDF]

Journal of the National Comprehensive Cancer Network, 2011
Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
Kenneth C, Anderson, Melissa, Alsina, William, Bensinger, J Sybil, Biermann, Asher, Chanan-Khan, Adam D, Cohen, Steven, Devine, Benjamin, Djulbegovic, Edward A, Faber, Cristina, Gasparetto, Carol Ann, Huff, Adetola, Kassim, Bruno C, Medeiros, Ruby, Meredith, Noopur, Raje, Jeffrey, Schriber, Seema, Singhal, George, Somlo, Keith, Stockerl-Goldstein, Steven P, Treon, Guido, Tricot, Donna M, Weber, Joachim, Yahalom, Furhan, Yunus   +23 more
  +10 more sources

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

Cells, 2022
Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients.
Megan Johnstone, Delaney Vinaixa, Marcello Turi, Eugenio Morelli, Kenneth Carl Anderson, Annamaria Gulla   +5 more
doaj   +1 more source

Multiple myeloma in people of working age in Czechia, Germany, and Poland: findings from a qualitative interview study [PDF]

, 2023
Purpose The study sought to understand the experiences of working age adults with myeloma and their partner/family members, living in Czechia, Germany, and Poland.
Forbat, Liz
core   +1 more source

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma

Frontiers in Oncology, 2022
AimsTo evaluate abnormal metabolites related to treatment response and prognosis of multiple myeloma (MM) patients through ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS).MethodsForty-six symptomatic MM patients were included ...
Yujun Wei, Jinying Wang, Fei Chen, Xin Li, Jiajia Zhang, Man Shen, Ran Tang, Zhongxia Huang   +7 more
doaj   +1 more source

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

Blood Cancer Journal, 2022
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai   +13 more
doaj   +1 more source

Multiple myeloma

Journal of the American Academy of Physician Assistants, 2015
This article presents a review of multiple myeloma, precursor states, and related plasma cell disorders. The clinical roles of fluorodeoxyglucose PET/computed tomography (CT) and the potential to improve the management of patients with multiple myeloma are discussed.
Christoph, Röllig, Stefan, Knop, Martin, Bornhäuser   +2 more
  +9 more sources

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

Cancer Medicine, 2022
Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen, Jiajia Zhang, Ran Tang, Yuhao Wang, Xiaokai Zhan, Sibin Fan, Zhongxia Huang, Yuping Zhong, Xin Li   +8 more
doaj   +1 more source

Multiple Myeloma

Hematology/Oncology Clinics of North America, 2014
Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes.
Sarah A, Holstein, Hong, Liu, Philip L, McCarthy   +2 more
  +7 more sources